"Cost per hour" has nothing to do with efficacy.

what do you mean, "Oxford continues to do trials?"

Oxford is trying to do ONE trial with the ActiPatch, and they can't find enough participants. There are no other "Oxford Trials" for the ActiPatch.

As for "the FDA is working with the studies in hand," it's not a "Period." it's an ellipsis. Here's the latest, from BIEL's October 10th press release:

The Agency has been "assessing" the registry data since July:
http://www.bielcorp.com/bioelectronics-company-update-july-22-2016/

After reviewing the registry data for three months, the FDA still won't accept it. So, "working with the studies in hand" doesn't exactly tell the story, "period," don't you agree?

You realize, I assume, that Oxford needs half of the devices to be placebo devices? Let me guess, you think they buy those off eBay, just as you told me that the ActiPatch I bought on eBay had to be a placebo? Remember that?

If you read the company updates, you will see that the FDA, after reviewing the Real World Evidence, asked for another blinded controlled trial for a part of the body other than the knee or foot. BIEL is still trying to get the FDA to accept the Real World Evidence but Real World Evidence is not a blinded controlled trial.

So it's a shame that the Oxford Study isn't done yet. BIEL could really have used it, even with only 30 participants.

I don't think that's funny at all. Who told you "the results are in?" Because the researcher and BIEL both told me that the study is still recruiting. BIEL told me the researchers are not allowed to advertise so they are having trouble finding participants.

It's NOT another study. It is ClinicalTrials.gov identifier: NCT02601807

https://clinicaltrials.gov/ct2/show/NCT02601807?term=actipatch+back+pain&rank=1

The Oxford Study is still recruiting.

That means the results are a LONG way off -- assuming they eventually recruit enough participants and finish the study.

Interesting development on the usacst.com site:

They removed the section about the labs in California.

The main page used to have eight links -- now it has seven. So, SOMEBODY is updating that site.

They made the same change to cstamdl.com. No other changes to either site.

I wouldn't be surprised to see usacst.com (and perhaps even catamdl.com) return to the public view. That link to the "labs in California" was the one chink in their armor.

True. And some of the current RXPC shareholders will buy a ton of the new stock after a R/S just to average down.

I just wish they'd put something new on their CST website. It's all lies anyway -- why not make up some new lies just to keep us interested?

Hey living! good to hear from you!

that cstamdl website isn't "new" -- it's the same pages from the cstamdl website that's been blocked to North Americans for two years. Charter (well actually Brown, the web guy) hasn't made a single change to those web pages in the past two years.

I don't think Charter and Brown have done any actual work with DR-70 since they took over, and promptly buried, Radient.

I guess the aussies are trolling for new Yankee money? That will be difficult since they've been evicted from the Tustin address. I wonder what excuses they will give to a potential Yankee investor who wants to see the facilities in California.

I don't see why Charter and Brown (the BOD) would ever resurrect RXPC stock because they don't own any of it. But who knows.

The only thing we know for sure: Wolfie and DC will pump this thing until 2021, and beyond. They think Provista is still going to ride in on a white horse and make them rich. I guess. Who knows, it looks like Wolfie is going to pump the Aussie site now, which is hilarious! Good ol' Wolfman does not disappoint!

That's funny! YOU calling ME paranoid!

RXPC shareholders weren't scammed out of your money. They simply gambled and lost. That's the way the pinksheets work.

I guess that some naive "investors" believed Wolfie and DC's nonsense about reverse backdoor creeping takeovers. But Wolfie and DC didn't take their money - those two lost as much as, or more than, everyone who believed their nonsense.

Or, to simplify: NO royalties.

Who, in your mind, is in the group of "you crooks?"

Do you think someone on a message board took your money?

Did you participate in the Class Action?

QUICK! check out this website before it gets blocked by 403 security:

www.usacst.com

this is new, registered on September 28 2016

it's just a clone of cstamdl.com

old git, you should visit this MB:
http://www.investorvillage.com/smbd.asp?mb=16561

Wolfie and DC are still Pumpin' the Dream over there. If you want to feel good about your "investment," that is the place to be.

I think that you and those two are the last three people on earth waiting for "benefits to be received by shareholders at a later date."

Slightly higher than the RP but still less than the QW.

No, the trademark protects only the name.

The "ingredients" were protected by a patent that has expired.

It doesn't matter whether you are in a hurry or not, old git. "Never" means "Never."

I revised it to $525k, friend.

And you predicted $0. Let's see who is closer. You still might be! A tip of the cap to YOU in that case!

("the deal in Sweden," oh brother.)

Thanks! I expected no more and no less.

Add the following to your list:

* fabricated photoshopped actipatch ads of ballerina feet
* fabricated bar charts showing fabricated data

You forgot Crystals in your bar chart!

ActiPatch works 3.5x better than Crystals in relieving pain!

ActiPatch works 4x better than voodoo, and 5x better than sasquatch saliva, but I realize you're tight on space. I mean look how big that is! it takes up the whole screen! Wow!

Please add Crystals to your wonderful bar chart ASAP and republish. Thanks in advance!

I'm going to hate myself for asking.....

But can you explain the statement "You are actually proving the statistics?"

Here's how I see your logic:

You: "73% of trial users buy a retail version."
Me: "BIEL's revenues prove that is a lie."
You: "You are in the 27%! You are actually proving the statistics!"

Let's take a different approach to this puzzle. Read this:
http://www.bielcorp.com/investors/letter-from-the-president/

Staelin says these things on October 22, 2015:

I don't know how much revenue BIEL reports per retail unit -- should we say $15? Let's do the math with these more realistic numbers:

50% of 80,000 = 40,000 users
each buys 2.5 additional units in the following year
40,000 * 2.5 * $15 = $1.5 million revenues

$1.5 revenues in the UK from the retail version in any given 12-month period? Didn't happen. And that is using the low-end estimate of 50%, not your 73% -- so you see, it's all BS.

What Whelan and Staelin are not telling you: how many people resonded to their survey? Maybe 10% of the 100,000 who bought the trial version? According to this source, a good response rate for an external survey is 10-15%.
https://www.surveygizmo.com/survey-blog/survey-response-rates/

Without knowing how many people responded to BIEL's survey, that 73% number is useless. Bottom line: in the UK, 2016 Q1 sales were 10% lower than 2015 Q1 sales. That alone tells us that 73% of trial-version customers are not returning to buy 2.5 retail units in the following 12 months.

Who cares about your bar charts, you ask?

I think we all know the answer to THAT.

Gladly. Although that;'s got to be it for me tonight -- I have other commitments so I don't have the luxury of sitting on this MB and responding to every post within five minutes.

That's a marketing piece from Bulgaria? What were the revenues from Bulgaria last quarter?

Oh drat, we don't know the revenue breakout by region. Funny, you'd think a company with Top Notch Lawyers would figure out a way to keep their investors in the loop.

The question: Who is buying?

The answer is right here in this post to which I am responding.

It's never a good sign when most, if not all, of the buying is done by existing shareholders.

Let's analyze the wonderful bar chart #2.

1. "Percent Responders of Recommend ActiPatch - Repurchase ActiPatch" was translated from what language into English?

2. Again, the numbers on the bars 73% don't match the numbers on the Y-Axis. SO annoying.

3. Whelan and Staelin claim that 73% of the Trial Version users came back and bought over 2 retail-priced version each. They stated this but never substantiated this. It's hype, and that is a kind word for it.

Think about it: BIEL claims they sold 100,000 trial versions since October 2014, right?

-> 100,000 * $5 = $500,000 revenues from the Trial Version (sounds plausible)

73% of those 100,000 customers should have bought an average of two each at $35:

100,000 * $35 * 2 * 0.73 = $5,110,000

Where do YOU see $5 million in revenues?

What I see: revenues in the UK decreasing by 10% -- and then BIEL stopped disclosing the revenues by region.

Let's analyze this wonderful bar chart.

1. Where did this data come from? Was it fabricated? I mean seriously... NSAIDS and acetaminophen ARE analgesics. And... MAGNETS?

2. There is NO way the ActiPatch reduces pain 3x better than opioids (analgesics, apparently). Anyone who believes THIS has never taken opioids.

3. The numbers on the bars don't match the numbers on the Y-axis. Example: 3.53 for ActiPatch falls short of 3.5 on the Y-axis. I hate bar charts that make this mistake. Who made this graph?

4. Heat wrap? Cold works much better for pain that heat. Where is ice-pack therapy on this bar graph? Ice is hard to apply sometimes but it works better on localized pain than practically every therapy on this chart.

I always wondered if Wolfman was actually Kenman.

Look at the similarities. Both illiterate and uneducated..... both of them got fooled into buying the stock by misinterpreting a press release.... and both bragged about having a "following." Wolfie called his bunch the "wolfpack." I used to call Kenman's fictional group "the Kenmen."

Kenman, leading an Army of Kenmen into the valley of darkness.

That's a trademark, old git, not a patent.

A trademark just prevents someone else from using a name. In the case of DR-70 or Onko-Sure, WHO CARES if someone else uses the name? Each of those names was an EPIC failure in the world of medicine.

EPIC.

Dive into the dumpsters -- WHY?

* for a couple of boxes of "Get Your Rear In Gear" t-shirts?
* for copies of the expired DR70 patents?

If AMDL ever makes a move, that won't affect you because you don't own AMDL stock. The Aussies own AMDL -- they call it CSTAMDL -- and even THAT appears to be dead now.

your RXPC stock will never be worth anything again. I think that even Wolfie and DC have come to this realization.

No, that's not how clinical trials are conducted.

The original trial is still recruiting. Here are the identifiers:

ClinicalTrials.gov Identifier: NCT02601807
Other Study ID Numbers: 15/LO/0926


If Oxford was conducting "ongoing trials beyond their initial trial" the new trials would have new ID numbers.

If a researcher went rogue, as you are suggesting, and started spending grant money on ANYTHING other than for what the money was granted, that researcher would be finished in the profession -- good luck EVER getting another grant.

Finally -- I asked BIEL and they said "The Oxford trial is still under way."

Face it -- the Oxford Trial is a long way from completion, and if they haven't enrolled 30 participants yet, it may NEVER get completed.

(p.s. the word is "imminent" not "eminent")

The FDA doesn't like testimonials and surveys.

I don't like them either. Look how many testimonials exist for sasquatch sightings in North America. Science says primates are only found between the Tropic lines, but the Bigfoot Believers don't need Science to tell them what they saw and felt.

No, I like the Scientific Method, and so does the FDA.

The Oxford Trial is a great Litmus test.

Some on this board, like me, say "I contacted Oxford and they told me the trial is still recruiting."

Others on this board say "BIEL told me the trial is completed" or "Oxford told me the trial is completed."

One of these groups is lying. Anyone who wants to know who is lying, and therefore whom to trust, can simply contact Oxford and ask.

Knowledge is power.

Who cares about the Oxford trial?

Anyone who wants to treat this as an "investment" instead of a lottery ticket.

"Oxford results in October" has proven to be just one more bit of hype that didn't materialize -- like the NHS tariff, and FDA OTC clearance, and profitability.

The fact that the Oxford Trial is still recruiting in November 2016 makes a difference, to some.

I got the exact same response from Oxford. I replied that I would love to participate (my shoulder pain is chronic) but I'm in the USA.

Anyone else who takes the time to do their own DD and contacts that researcher will get the exact same response.

The truth is empowering.

and trying to catch a falling knife leaves scars.

No, YOUR post is incorrect. I got the EXACT same response from the Oxford contact. So will anyone else who sends a question to the contact.

I also got a response from BIEL saying "The Oxford trial is still under way, their ethics committee prohibits the investigators from advertising for subjects so it is a volunteer-only basis." (Comma splice theirs, not mine.)

BIEL also told me that the press release statement about "three ActiPatch randomized clinical trials" is wrong. There are only two ActiPatch randomized clinical trials. So I guess we have to question every statement in those Grace Holding press releases. How tedious.

Bottom line -- the Oxford results are a LONG way off, and if they are still recruiting, that trial may NEVER get to the data collection stage.

Which is a shame because I was certain that would be the catalyst for BIEL to disclose that the FDA OTC application has changed to a de novo. Now... who knows.

One thing we know -- Q3 financial results "soon" (Nov 15th) and SEC results "soon" (December).

The NHS tariff for November is out - and still no RecoveryRx. So, wat's the excuse THIS month?

That is the consensus.

I can't get the Oxford contacts to respond.

You are asking the FDA the wrong questions.

Ask the FDA "Is the ActiPatch device cleared for ANYTHING, prescription or otherwise?" and they will tell you.

THE ACTIPATCH IS NOT CLEARED FOR PRESCRIPTION BY THE FDA.

Ask the FDA. I did. BIEL's only prescription clearance is for the ActiBand, for treatment of swelling after blepharoplasty.

We agree that the argument concerning (is the 510(k) dead or not?" is all conjecture.

Your conjecture is well-reasoned and eloquent. The part of your conjecture that I disagree with the MOST is this:

"The FDA did not change their "Belief" into a "Final Decision" because they knew it would not hold up if they had to face GP in a court of law."

Here's why. I assume we agree that the FDA told BIEL this in May 2016:

And I assume we agree that the FDA told BIEL this on June 8th:



I think we agree that the FDA said these things, because if we can't believe THESE statements of fact, we can't believe ANYTHING in ANY of BIEL's Company Updates, and there's no point in discussing this further, because BIEL's Company Updates contain lies.

So, according to your logic, the FDA told BIEL "the agency would be back to the company shortly with its pathway determination" but then did NOT do this because "they knew it would not hold up if they had to face GP in a court of law."

I can't accept that. I don't believe the FDA is afraid of facing GP in a "court of law." The FDA does what the FDA thinks is right and that brings it into court, fine.

I think we will see who is right only when one of these happens:

-> the FDA clears the 510(k).

or

-> BIEL discloses that the application has changed to a de novo.